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Abstract 
Colorectal cancer is the second most frequently diagnosed cancer in Spain. Cancer 
treatment and outcomes can be influenced by tumor characteristics, patient general health status 
and comorbidities. Numerous studies have analyzed the influence of comorbidity on cancer 
outcomes, but limited information is available regarding the frequency and distribution of 
comorbidities in colorectal cancer patients, particularly elderly ones, in the Spanish population. 
We developed a population-based high-resolution cohort study of all incident colorectal cancer 
cases diagnosed in Spain in 2011 to describe the frequency and distribution of comorbidities, as 
well as tumor and healthcare factors. We then characterized risk factors associated with the most 
prevalent comorbidities, as well as dementia and multimorbidity, and developed an interactive 
web application to visualize our findings. The most common comorbidities were diabetes 
(23.6%), chronic obstructive pulmonary disease (17.2%), and congestive heart failure (14.5%). 
Dementia was the most common comorbidity among patients aged ≥75 years. Patients with 
dementia had a 30% higher prevalence of being diagnosed at stage IV and the highest prevalence 
of emergency hospital admission after colorectal cancer diagnosis (33%). Colorectal cancer 
patients with dementia were nearly three times more likely to not be offered surgical treatment. 
Age ≥75 years, obesity, male sex, being a current smoker, having surgery more than 60 days 
after cancer diagnosis, and not being offered surgical treatment were associated with a higher 
risk of multimorbidity. Patients with multimorbidity aged ≥75 years showed a higher prevalence 
of hospital emergency admission followed by surgery the same day of the admission (37%). We 
found a consistent pattern in the distribution and frequency of comorbidities and multimorbidity 
among colorectal cancer patients. The high frequency of stage IV diagnosis among patients with 
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dementia and the high proportion of older patients not being offered surgical treatment are 
significant findings that require policy actions. 
 
Introduction 
Cancer accounted for 9.6 million deaths globally in 2018, and was the second most 
common cause of death in the world [1]. Colorectal cancer (CRC) is the most frequently 
diagnosed cancer in Spain, with 37,172 newly diagnosed cases in 2018 [2]. Despite the high 
prevalence of CRC in the elderly, the inclusion of this cohort in clinical trials is 
disproportionately low [3]. In addition to clinical and pathological characteristics of the tumor, 
general health status and comorbidities of patients also influence cancer treatment and outcomes. 
Comorbidity describes the existence of a long-term health condition or disorder in the presence 
of a primary disease of interest, such as cancer [4], whereas multimorbidity refers to the 
existence of more than one comorbid condition [5]. Comorbidity and multimorbidity are 
increasingly seen as a problem of the elderly, but have also been reported as occurring more 
often and at a younger age in patients of lower socioeconomic status [6, 7]. The presence of 
comorbidities can influence treatment options, and therefore should be thoroughly evaluated 
when studying prognosis, outcomes, and mortality in cancer patients. Despite the coexistence of 
health conditions being commonplace, the guidelines and delivery of care appear to be focused 
on single disease management [8, 9]. However, effective management of comorbid conditions is 
important in maintaining patients’ optimal health status, as the presence of one could contribute 
to the development of another [10], and decisions regarding cancer treatment require the 
consideration of patients’ comorbidities [11, 12]. Furthermore, post-operative complications 
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have been reported as higher in patients with comorbidity [13], and certain comorbid conditions 
have been linked to adverse outcomes following surgery for cancer [14].  
 
As noted above, there is consistent evidence on the influence of comorbidities on cancer 
outcomes, but little is known about them in CRC patients. Thus, we aimed to describe the 
frequency and distribution of comorbidities and multimorbidity, as well as their associated risk 
factors in the cohort of all CRC incident cases diagnosed in Granada and Girona (Spain) in 2011.  
 
Materials and methods 
Study design, participants, data, and setting 
We conducted a population-based cohort study including all CRC incident cases (C18-
C21), according to the International Classification of Diseases for Oncology, 3rd Edition, (ICD-
O-3), diagnosed in 2011 and followed up until December 31, 2016 from two population-based 
Spanish cancer registries (Girona and Granada). Data were obtained from hospital medical 
records following a detailed protocol from the European High Resolution studies collaboration 
(TRANSCAN-HIGHCARE project within ERA-Net) [15]. We recorded information regarding 
the cancer stage at diagnosis (TNM staging system, 7th edition), cancer diagnostic exams, tumor 
morphology, cancer treatment, patients' comorbidities, performance status, and vital status. All 
recorded comorbidities were extracted 6 months before the index cancer was diagnosed, based 
on a standardized protocol published elsewhere [16]. All information was classified as either 
patient, tumor, or healthcare factors. Our study proposal (CP17/00206) was titled “Comorbidities 
and Associated Risk Factors among Colorectal Cancer Patients in Spain” (CoMCoR), and 
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approved by an internal review board and an ethical review committee with internal number 
0072-N-18. 
 
 
Variables related to the patient’s characteristics 
We recorded patient’s age, sex, smoking status, body mass index (BMI), performance 
status, comorbidities, and multimorbidity. Age at diagnosis was categorized into four age groups: 
<55, 55-64, 65-74, and ≥75 years. Smoking status was categorized as current, previous, and 
never smoker. BMI was categorized as normal (<25.0 kg/m2), overweight (≥25.0 kg/m2 and <30 
kg/m2), and obese (≥30 kg/m2). Patients’ performance status was ascertained using the Eastern 
Cooperative Oncology Group (ECOG) scale and categorized as normal (0); restricted but able to 
carry out light work (1); restricted, unable to work but capable of self-care (2); restricted, capable 
of limited self-care (3); and disabled (4) [17]. Comorbidities were classified based on the Royal 
College of Surgeons modified Charlson score that reduces the number of comorbidities to 12 
(myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular 
disease, dementia, chronic obstructive pulmonary disease (COPD), rheumatic disease, liver 
disease, diabetes mellitus, hemiplegia/paraplegia, renal disease and AIDS/HIV), removing some 
categories such as peptic ulcer disease (since it is not considered a chronic disease anymore), and 
grouping diseases together (e.g., diabetes mellitus codes with or without complications are 
grouped into one category). Furthermore, the score drops the weighting of comorbidities, and 
instead categorizes the number of comorbidities in three categories: 0, 1, and ≥2 as a 
multimorbidity indicator [18].  
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Variables related to tumor characteristics 
We recorded the tumor topography, morphology, grade of differentiation, and stage at 
diagnosis. The final stage variable was defined as the combination of clinical and pathological 
TNM stages and categorized into five groups, based on the 7th edition of the TNM manual. 
Topography, grade of differentiation, and morphology were coded according to ICD-O-3. 
Variables related to healthcare provision factors 
We recorded the type of hospital admission, surgery, type of surgery, and time to surgery. 
Type of hospital admission indicated whether cancer patients had an emergency or planned 
admission. The type of surgery was dichotomized as major or minor, and the time to surgery was 
noted as the number of days from the date of cancer diagnosis to the date patients had the 
surgical intervention and categorized into five groups (0, 1 to <14, 14 to 30, 31 to 59 and ≥60 
days). Emergency surgery was defined as surgery offered on the same day of an emergency 
hospital admission.  
 
Statistical analysis 
First, we calculated the prevalence of each of the 12 different comorbidities for the cohort 
of CRC patients. Then, we calculated the frequency and distribution of comorbidities by patient, 
tumor and healthcare factors using counts and proportions. The Chi-square, Fisher’s exact, and 
score tests were used for statistical inference. We assumed missing data, in a completely at 
random pattern, and thus performed a complete case analysis. Afterward, we computed 
unadjusted, sex-adjusted, and age-adjusted comorbidity prevalence ratios (PRs) with 95% 
confidence intervals (CIs) by patient, tumor, and healthcare factors. Generalized linear models 
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with Poisson distribution and log link were fitted for the five most common comorbidities plus 
dementia. We included the specific comorbidity indicator as the dependent variable; patient, 
tumor, and health care factors were the independent variables [19]. To describe the risk factors 
associated with the presence of multimorbidity (≥2 chronic conditions vs. non-comorbidities) we 
fitted a multinomial logistic regression model using the Royal College of Surgeons modified 
Charlson score as the dependent variable, with patient, tumor, and health care factors as 
independent variables. Risk factors associated with multimorbidity were evaluated using non-
comorbidity as the reference category. Then, we derived unadjusted, age-adjusted, and sex-
adjusted risk ratios (ARRs) with 95% CIs. Finally, we developed an open source web application 
using advanced visualization tools (radar plots, heat maps and forest plots) [20] to reduce the 
dimensionality of the data and display the results for the ten most common comorbidities plus 
dementia, available at http://watzilei.com/shiny/CoMCoR/. Furthermore, we created a GitHub 
repository where the code used to develop the analysis and the web application can be accessed 
for reproducibility (https://github.com/migariane/CoMCoR).  
 
Results 
Patient and tumor characteristics 
Table 1 shows the distribution of patient, tumor, and healthcare characteristics from the 
cohort of colorectal cancer patients under study. More than half (59%) of colorectal cancer 
patients had one or more comorbidities 6 months before cancer diagnosis, and 30% had 
multimorbidity. Men represented 61% of the cohort, 67% of patients were age >65 years, 12% 
had a restricted performance status, slightly more than half of them were previous or current 
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smokers (52%), and 49% were overweight or obese. The prevalence of the different tumor 
locations was 34% in the right colon, 32% in the left colon, and 33% in the rectum. The 
differentiation of the tumor was mostly grade two (56%); however, 19% of the tumors were not 
graded. Only 16% of colorectal cancer patients had a stage I tumor at diagnosis, while more than 
50% of the cases were identified as stage III/IV. Six percent of patients had missing stage 
information. The type of hospital admission was principally planned (65%), and almost one out 
of five patients were admitted after visiting the hospital emergency department. Surgery was 
performed in 83% of the patients, and the most frequent type of surgery was major surgery 
(77%). The time to surgery exceeded 60 days for 26% of the patients. Sixteen percent of the 
colorectal cancer cases had emergency surgery (Table 1). 
  
Table 1. Distribution of patient, tumor and healthcare characteristics among all incident colorectal cancer patients in Granada and Girona, 
2011, n = 1,061 
Patient's characteristics  N(%) Healthcare factors N(%) Tumor's characteristics N(%) Comorbidities* N(%) 
Age in years 
 
Type hospital admission  
 
Anatomical subsite 
 
Multimorbidity Prevalence 
<55 130(12.3) Emergency 183(17.2) Right colon 357(33.6) None 413(38.9) 
55 - 64 219(20.6) Planned  693(65.3) Left colon 340(32.1) One 301(28.4) 
65 - 74 272(25.6) Missing 185(17.4) Colon Unspecified 11(1.0) Two 190(17.9) 
≥75 440(41.5) Surgery  
 
Rectal 353(33.3) Three 89(8.4) 
Sex 
 
Done 879(82.8) Grade of differentiation 
 
Four 30(2.8) 
Male 644(60.7) Not done 175(16.5) One 168(15.8) Five  11(1.0) 
Female 417(39.3) Missing 7(0.7) Two 596(56.2) Six  4(0.4) 
Performance status ECOG score 
 
Type of Surgery  
 
Three 90(8.5) Missing 23(2.2) 
Normal (0)  259(24.4) Not done 175(16.5) Four 7(0.6) 
  Restricted but able to carry out light work (1) 423(39.9) Major 816(76.9) Missing 200(18.9) 
  
Restricted, unable to work but capable of selfcare 
(2) 83(7.8) Minor 43(4.1) Stage TNM 
   Restricted, capable of limited selfcare (3) 35(3.3) Done but uknown type 20(1.9) I 168(15.8) 
  Disabled (4) 6(0.6) Missing 7(0.7) II 281(26.5) 
  Missing 255(24.0) Time to surgery in months  
 
III 285(26.9) 
  Smoking status 
 
Emergency 0 days 171 (16.1) IV 267(25.2) 
  Current 130(12.3) 1 to <14 days 115(10.8) Missing 60(5.6) 
  Previous 298(28.1) 14 to 30 days 124(11.7) 
     Never 505(47.6) 31 to 59 days 188(17.7) 
     Missing 127(12.0)  60 and more days 280(26.4) 
     BMI in kg/m2 
 
Missing 8 (0.8) 
     
<25 226(21.3) No surgery  175 (16.5) 
     25.0 - 29.9 327(30.8) 
        
≥30 193(18.2) 
        Missing 315(29.7)                   
* Comorbidity score based on:  Armitage JN, van der Meulen JH. Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score. The British journal of 
surgery. 2010 May;97(5):772-81. 
  
 Supporting information Table S1 shows the prevalence of comorbidities among CRC 
patients at least 6 months before the cancer diagnosis, ordered by frequency. Diabetes mellitus, 
COPD, and congestive heart failure were the most common comorbidities among CRC patients 
(24%, 17%, and 15%, respectively). Figure 1 shows the distribution of the prevalence of the top-
ten comorbidities by sex. The most common comorbidity among men was COPD and 
rheumatologic disease and dementia among women. 
 
Figure 1. Radar plot displaying the prevalence of comorbidities by sex among all incident 
colorectal cancer patients in Granada and Girona, 2011, n = 1,061 
 
Figure 1 [here] 
 
Figure 2 shows the distribution of the prevalence of the top-ten comorbidities by age. The most 
common comorbidity among elderly (age ≥75 years) was dementia and liver disease among 
patients aged <55 years. 
 
Figure 2. Heat map displaying the prevalence of comorbidities by age among all incident 
colorectal cancer patients in Granada and Girona, 2011, n = 1,061 
 
Figure 2 [here] 
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Figure legend. Comorbidities: I Myocardial infarct; II Congestive heart failure; III Peripheral 
vascular disease; IV Cerebrovascular disease; V Dementia; VI Chronic pulmonary disease; VII 
Rheumatic disease; VIII Liver disease; IX Diabetes mellitus; XI Renal disease. 
Table 2 shows the frequency and crude prevalence ratio of comorbidities for the five most 
common comorbidities plus dementia by tumor, patient, and health. Supporting information 
Table S2 shows sex-adjusted and age-adjusted comorbidity prevalence ratios by tumor, patient, 
and health care factors. The complete distribution of comorbidities is provided as supporting 
information (Supplementary Tables S3, S4, and S5). 
 
Distribution and frequency of comorbidities by tumor characteristics  
The pattern of comorbidities by sex shows a high prevalence of COPD among male 
colorectal cancer patients (79%), while almost 60% of patients with dementia or rheumatologic 
disease were female. There was a frequency gradient of comorbidities by age, with dementia 
(75%), congestive heart failure (64%), and renal disease (46%) as the most common 
comorbidities among the elderly. Patients' performance status varied among comorbidities as 
well. Ninety-two percent of liver disease patients and 80% of diabetes patients had ECOG 
performance score 0 or 1, in contrast to only 53% of dementia and 30% of congestive heart 
failure patients. There was strong evidence supporting a significant trend of comorbidity 
prevalence across the levels of performance status for the five most common comorbidities plus 
dementia. Furthermore, COPD, diabetes, and dementia were more frequently associated with 
smoking (current and previous): 68%, 53%, and 36%, respectively. Adjusted PRs (APRs) 
comparing current smoker vs. never smoker in COPD, diabetes, and dementia were 3.1 (95% CI: 
1.9-5.0), 1.3 (95% CI: 0.8-2.0), and 1.8 (95% CI: 0.6-5.2), respectively. Overweight and obesity 
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were more prevalent among patients with congestive heart failure (81%), peripheral vascular 
disease (76%), and diabetes (77%). The respective comorbidity APRs comparing a BMI 30 
kg/m2 vs. <25 kg/m2 were 2.1 (95% CI: 1.2-3.6) for congestive heart failure, 1.7 (95% CI: 1.0-
2.7) for peripheral vascular disease, and 1.7 (95% CI: 1.2-2.4) for diabetes. However, patients 
with dementia showed the highest prevalence of underweight and normal weight (body mass 
index <25 kg/m2) patients (41%) (Tables 2 and S2). 
 
Distribution and frequency of comorbidities by tumor’s characteristics 
The most prevalent comorbidity in right colorectal cancer patients was dementia (44%) 
and rheumatic disease for rectal cancer patients (38%). Regarding the grade of differentiation, 
the most common grade for all the different comorbidities was grade two (moderately 
differentiated). However, diabetes had the highest proportion of grade three (30%) and an APR 
of 1.4 (95% CI: 0.9-2.0) comparing grades three-four vs. one. Overall, all comorbidities had 
approximately 55% of cancer cases diagnosed at stages III or IV. Patients with COPD showed 
the lowest frequency of stage IV (22%). CRC patients with dementia had a 30% higher 
prevalence of advanced cancer diagnosis i.e. APR 1.3; 95% CI: 0.5-3.2 comparing stage IV vs I 
(Tables 2 and S2). 
 
Distribution and frequency of comorbidities by healthcare characteristics  
Patients with dementia showed the highest prevalence of emergency hospital admission 
after CRC diagnosis (33%) with an APR comparing planned vs. emergency admission of 1.6 
(95% CI: 1.1-2.2). Despite the emergency admission, dementia was the comorbidity with the 
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highest prevalence of patients who were not offered surgery as treatment (64%) with an APR of 
2.1 (95% CI: 1.2-3.8). Note that patients with dementia also showed the second highest 
prevalence of stage IV, with 30% of the cases. However, patients with rheumatologic disease 
showed the highest prevalence of major surgery (91%) and also the highest APR for minor 
surgery (2.0; 95% CI: 1.0-3.7). Major surgery was the most common type of surgery among all 
CRC patients, with at least 90% for all comorbidities. The pattern of time to surgery by 
comorbidities showed considerable variability. Overall, among the majority of comorbidities, 
one-third of CRC patients were offered surgery 60 or more days after the cancer diagnosis. 
However, dementia patients showed a different pattern: 30% had emergency surgery the same 
day as hospital admission (time to surgery of zero days). CRC with congestive heart failure 
showed the highest APR (1.7; 95% CI: 1.0-2.9) comparing surgery more than 60 days vs. 
emergency surgery (zero days) (Tables 2 and S2). 
 
  
Table 2.   Distribution and frequency of the top five comorbidities plus dementia and associated risk ratios by patient, tumor and 
healthcare characteristics among all incident colorectal cancer patients in Granada and Girona, 2011, n = 1,061 
 
  
II III V VI VII IX 
  
  n(%) PR(95%CI) P-value n(%) PR(95%CI) P-value n(%) PR(95%CI) P-value n(%) PR(95%CI) P-value n(%) PR(95%CI) P-value n(%) PR(95%CI) P-value 
Patient's factors  Total                         
Age in years     
 
<0.001*   
 
0.036*   
 
<0.001*   
 
<0.001*   
 
0.006*   
 
<0.001* 
<55 130 4(2.6) (Reference)   9(7.3) (Reference)   2(4.2) (Reference)   8(4.4) (Reference)   6(5.8) (Reference)   6(2.4) (Reference)   
55 - 64 219 17(11) 2.5(0.9, 7.4)   22(17.7) 1.5(0.7, 3.1)   5(10.4) 1.5(0.3, 7.6)   21(11.5) 1.6(0.7, 3.4)   13(12.5) 1.3(0.5, 3.3)   42(16.8) 4.2(1.8, 9.6)   
65 - 74 272 34(22.1) 4.1(1.5, 11.3)   36(29.0) 1.9(1.0, 3.9) 
  
5(10.4) 1.2(0.2, 6.1)   57(31.3) 3.4(1.7, 7.0)   30(28.8) 2.4(1.0, 5.7)   86(34.4) 6.9(3.1, 15.4)   
≥75 440 99(64.3) 7.6(2.8, 20.2)   57(46.0) 1.9(1.0, 3.8)   36(75.0) 5.5(1.3, 22.6)   96(52.7) 3.7(1.8, 7.3)   55(52.9) 2.8(1.2, 6.4)   116(46.4) 5.9(2.7, 13.1)   
Sex     
 
0.635   
 
0.870   
 
0.014   
 
<0.001   
 
<0.001   
 
0.004 
Male 644 96(62.3) (Reference)   76(61.3) (Reference)   21(43.8) (Reference)   143(78.6) (Reference)   42(40.4) (Reference)   171(68.4) (Reference)   
Female 417 58(37.7) 0.9(0.7, 1.3)   48(38.7) 1.0(0.7, 1.4)   27(56.3) 2(1.1, 3.5)   39(21.4) 0.4(0.3, 0.6)   62(59.6) 2.3(1.6, 3.3)   79(31.6) 0.7(0.6, 0.9)   
Performance status     
 
<0.001*   
 
<0.001*   
 
<0.001*   
 
0.001*   
 
0.062*   
 
0.005* 
Normal (0)  259 20(16.0) (Reference)   12(12.6) (Reference)   1(3.3) (Reference)   25(17.9) (Reference)   19(19.0) (Reference)   45(22.3) (Reference)   
Restricted but able to  
carry out light work (1) 423 68(54.4) 2.1(1.3, 3.3)   62(65.3) 3.2(1.7, 5.7)   13(43.3) 7.9(1.0, 60.4)   89(63.6) 2.2(1.4, 3.3)   66(66.0) 2.1(1.3, 3.4)   117(57.9) 1.6(1.2, 2.1)   
Restricted, unable to 
work but capable 
of selfcare (2) 
83 21(16.8) 3.3(1.9, 5.8)   10(10.5) 2.6(1.2, 5.8)   8(26.7) 25.2(3.2, 198.3)   16(11.4) 2.0(1.1, 3.6)   9(9.0) 1.5(0.7, 3.2)   25(12.4) 1.7(1.1, 2.7)   
Restricted, capable  
of limited selfcare (3) 35 12(9.6) 4.4(2.4, 8.2)   9(9.5) 5.5(2.5, 12.2)   6(20.0) 44.2(5.5, 356.6)   8(5.7) 2.4(1.2, 4.8)   4(4.0) 1.6(0.6, 4.3)   14(6.9) 2.3(1.4, 3.7)   
Disabled (4) 6 4(3.2) 8.6(4.2, 17.4)   2(2.1) 7.2(2.0, 25.2)   2(6.7) 86.0(9.0, 82.4)   2(1.4) 3.4(1.0, 11.3)   2(2.0) 4.5(1.3, 15.2)   1(0.5) 1.0(0.2, 5.8)   
Smoking status 255   
 
0.028   
 
0.858   
 
0.406   
 
<0.001   
 
0.001   
 
0.023 
Current 130 12(8.9) 0.7 (0.4, 1.3)   15(13.0) 0.9 (0.5, 1.6)   5(12.8) 0.8 (0.3, 2.0)   35(20.7) 2.5 (1.6, 3.9)   9(9.8) 0.5 (0.3, 1.0)   31(14.0) 1.2 (0.8, 1.7)   
Previous 298 55(40.7) 1.4 (1.0, 2.0)   35(30.4) 0.9 (0.6, 1.4)   9(23.1) 0.6 (0.3,1.3)   80(47.3) 2.5 (1.8, 3.5)   16(17.4) 0.4 (0.2, 0.7)   87(39.2) 1.4 (1.0, 1.9)   
Never 505 68(50.4) (Reference)   65(56.5) (Reference)   25(64.1) (Reference)   54(32.0) (Reference)   67(72.8) (Reference)   104(46.8) (Reference)   
BMI in kg/m2     
 
0.010*   
 
0.038*   
 
0.337*   
 
0.057*   
 
0.733*   
 
0.001* 
<25 226 17(19.5) (Reference)   23(23.5) (Reference)   12(41.4) (Reference)   40(30.8) (Reference)   22(32.4) (Reference)   40(23) (Reference)   
25.0 - 29.9 327 40(46.0) 1.6(0.9, 2.8)   42(42.9) 1.3(0.8, 2.0)   10(34.5) 0.6(0.3, 1.3)   41(31.5) 0.7(0.5, 1.1)   25(36.8) 0.8(0.5, 1.4)   74(42.5) 1.3(0.9, 1.8)   
≥30 193 30(34.5) 2.1(1.2, 3.6)   33(33.7) 1.7(1.0, 2.8)   7(24.1) 0.7(0.3, 1.7)   49(37.7) 1.4(1.0, 2.1)   21(30.9) 1.1(0.6, 2.0)   60(34.5) 1.8(1.2, 2.5)   
*Score test for trend. Comorbidities: II Congestive heart failure; III Peripheral vascular disease; V Dementia; VI Chronic pulmonary disease; VII Rheumatic disease; IX Diabetes mellitus  
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II III V VI VII IX 
  
  n(%) PR(95%CI) P-
value n(%) PR(95%CI) 
P-
value n(%) PR(95%CI) 
P-
value n(%) PR(95%CI) 
P-
value n(%) PR(95%CI) 
P-
value n(%) PR(95%CI) 
P-
value 
Tumor factors Total 
 
  
  
 
  
 
  
  
 
  
 
  
  
 
  
Anatomical  Site   
 
 
0.63   
 
0.913 
 
 
0.360   
 
0.390 
 
 
0.742   
 
0.195 
Right colon 357 55(35.7) (Reference) 
 
44(35.5) (Reference)   21(43.8) (Reference) 
 
67(36.8) (Reference)   31(29.8) (Reference) 
 
98(39.2) (Reference)   
Left colon 340 50(32.5) 1(0.7, 1.4) 
 
41(33.1) 1.0(0.7, 1.5)   11(22.9) 0.5(0.3, 1.1) 
 
63(34.6) 1.0(0.7, 1.3)   33(31.7) 1.1(0.7, 1.8) 
 
74(29.6) 0.8(0.6, 1.0)   
Colon Unspecified 11 2(1.3) 1.8(0.6, 6) 
 
1(0.8) 1.1(0.2, 7.1)   0(0) , 
 
1(0.5) 0.7(0.1, 4.7)   1(1.0) 1.6(0.3, 10.2) 
 
2(0.8) 1.0(0.3, 3.3)   
Rectal 353 47(30.5) 0.9(0.6, 1.2) 
 
38(30.6) 0.9(0.6, 1.3)   16(33.3) 0.8(0.4, 1.4) 
 
51(28.0) 0.8(0.6, 1.1)   39(37.5) 1.3(0.8, 2.0) 
 
76(30.4) 0.8(0.6, 1.0)   
Grade   
 
 
0.834*   
 
0.387* 
 
 
0.430*   
 
0.753* 
 
 
0.414*   
 
0.187* 
I 168 24(19.8) (Reference) 
 
19(18.4) (Reference)   3(9.1) (Reference) 
 
21(14.1) (Reference)   19(22.6) (Reference) 
 
36(17.6) (Reference)   
II 596 83(68.6) 0.9(0.6, 1.4) 
 
77(74.8) 1.1(0.7, 1.7)   27(81.8) 2.4(0.7, 7.8) 
 
116(77.9) 1.5(1, 2.3)   56(66.7) 0.8(0.5, 1.3) 
 
138(67.6) 1.0(0.7, 1.4)   
III 90 13(10.7) 1.0(0.5, 1.8) 
 
7(6.8) 0.7(0.3, 1.5)   2(6.1) 1.2(0.2, 7.0) 
 
12(8.1) 1.0(0.5, 2.0)   8(9.5) 0.7(0.3, 1.6) 
 
30(14.7) 1.5(1.0, 2.2)   
IV 7 1(0.8) 0.9(0.1, 6.0) 
 
0(0) -   1(3.0) 7.5(0.9, 63.5) 
 
0(0) -   1(1.2) 1.2(0.2, 7.7) 
 
0(0) -   
Stage   
 
 
0.600*   
 
0.372* 
 
 
0.650*   
 
0.621* 
 
 
0.235   
 
0.979* 
I 168 25(16.9) (Reference) 
 
18(14.8) (Reference)   6(14) (Reference) 
 
23(13.5) (Reference)   17(16.5) (Reference) 
 
34(14.4) (Reference)   
II 281 51(34.5) 1.2(0.8, 1.9) 
 
31(25.4) 1.0(0.6, 1.8)   13(30.2) 1.3(0.5, 3.4) 
 
57(33.3) 1.5(1.0, 2.3)   42(40.8) 1.5(0.9, 2.5) 
 
69(29.2) 1.2(0.9, 1.8)   
III 285 29(19.6) 0.7(0.4, 1.1) 
 
39(32.0) 1.3(0.8, 2.2)   11(25.6) 1.1(0.4, 2.9) 
 
54(31.6) 1.4(0.9, 2.2)   16(15.5) 0.6(0.3, 1.1) 
 
79(33.5) 1.4(1.0, 2.0)   
IV 267 43(29.1) 1.1(0.7, 1.7) 
 
34(27.9) 1.2(0.7, 2.0)   13(30.2) 1.4(0.5, 3.5) 
 
37(21.6) 1.0(0.6, 1.6)   28(27.2) 1.0(0.6, 1.8) 
 
54(22.9) 1.0(0.7, 1.5)   
Healthcare factors Total                                     
Type hospital admission   
 
 
0.685   
 
0.686 
 
 
0.084   
 
0.405 
 
 
0.259   
 
0.015 
Emergency 183 25(22.3) (Reference) 
 
19(19.2) (Reference)   10(33.3) (Reference) 
 
34(23.3) (Reference)   14(16.1) (Reference) 
 
30(14.7) (Reference)   
Planned  693 87(77.7) 0.9(0.6, 1.4) 
 
80(80.8) 1.1(0.7, 1.8)   20(66.7) 0.5(0.2, 1.1) 
 
112(76.7) 0.9(0.6, 1.2)   73(83.9) 1.4(0.8, 2.4) 
 
174(85.3) 1.5(1.1, 2.2)   
Surgery    
 
 
<0.001   
 
0.374 
 
 
<0.001   
 
0.288 
 
 
0.732   
 
0.865 
Done 879 113(73.9) (Reference) 
 
100(80.6) (Reference)   30(63.8) (Reference) 
 
147(80.8) (Reference)   88(84.6) (Reference) 
 
206(83.1) (Reference)   
Not done 175 40(26.1) 1.8(1.3, 2.5) 
 
24(19.4) 1.2(0.8, 1.8)   17(36.2) 2.8(1.6, 5.0) 
 
35(19.2) 1.2(0.9, 1.7)   16(15.4) 0.9(0.6, 1.5) 
 
42(16.9) 1.0(0.8, 1.4)   
Type of Surgery    
 
 
0.732   
 
0.637 
 
 
0.682   
 
0.325 
 
 
0.065   
 
0.242 
Major 816 108(95.6) (Reference) 
 
93(93.9) (Reference)   28(96.6) (Reference) 
 
140(96.6) (Reference)   79(90.8) (Reference) 
 
193(96.5) (Reference)   
Minor 43 5(4.4) 0.9(0.4, 2.0) 
 
6(6.1) 1.2(0.6, 2.6)   1(3.4) 0.7(0.1, 4.8) 
 
5(3.4) 0.7(0.3, 1.5)   8(9.2) 1.9(1.0, 3.7) 
 
7(3.5) 0.7(0.3, 1.3)   
Time to surgery in months    
 
 
0.125*   
 
0.027* 
 
 
0.045*   
 
0.181* 
 
 
0.166*   
 
0.018* 
Emergency 0 days 171 16(14.3) (Reference) 
 
15(15.2) (Reference)   9(30.0) (Reference) 
 
21(14.4) (Reference)   11(12.6) (Reference) 
 
32(15.6) (Reference)   
1 to <14 days 115 16(14.3) 1.5(0.8, 2.9) 
 
10(10.1) 1.0(0.5, 2.1)   5(16.7) 0.8(0.3, 2.4) 
 
19(13.0) 1.4(0.8, 2.4)   11(12.6) 1.5(0.7, 3.3) 
 
18(8.8) 0.8(0.5, 1.4)   
14 to 30 days 124 13(11.6) 1.2(0.6, 2.3) 
 
8(8.1) 0.8(0.3, 1.7)   4(13.3) 0.6(0.2, 2.0) 
 
24(16.4) 1.6(1.0, 2.8)   11(12.6) 1.4(0.6, 3.2) 
 
29(14.1) 1.3(0.8, 2.0)   
31 to 59 days 188 26(23.2) 1.5(0.8, 2.6) 
 
28(28.3) 1.7(0.9, 3.0)   7(23.3) 0.7(0.3, 1.8) 
 
32(21.9) 1.4(0.8, 2.3)   28(32.2) 2.3(1.2, 4.4) 
 
56(27.3) 1.6(1.1, 2.3)   
 60 and more days 280 41(36.6) 1.6(0.9, 2.7)   38(38.4) 1.6(0.9, 2.8)   5(16.7) 0.3(0.1, 1.0)   50(34.2) 1.5(0.9, 2.3)   26(29.9) 1.5(0.8, 2.9)   70(34.1) 1.3(0.9, 1.9)   
*Score test for trend. Comorbidities: II Congestive heart failure; III Peripheral vascular disease; V Dementia; VI Chronic pulmonary disease; VII Rheumatic disease; IX Diabetes mellitus  
  
 Table 3 shows the risk factors associated with the presence of multimorbidity versus the 
absence of comorbidities by patients, tumor, and healthcare factors. Overall, a higher risk of 
multimorbidity was associated with being aged ≥75 years, obese, male, or current smoker 
(Figure 3).  
 
Figure 3. Forest plot: Multimorbidity risk factors by patients’ age, sex, performance status and 
BMI among all incident colorectal cancer patients in Granada and Girona, 2011, n = 1,061 
 
Figure 3 [here] 
 
Likewise, being offered surgery more than 60 days after cancer diagnosis and not being offered 
surgery were associated with a higher risk of multimorbidity. It is important to highlight that 
37% of patients having emergency surgery had multimorbidity and were aged ≥75 years. 
Furthermore, 30% of emergency surgery was performed in older (≥75 years) advanced stage 
(III/IV) CRC patients affected by dementia. There was limited evidence supporting that patients 
with multimorbidity versus non-comorbidity had a 30% higher risk of not being offered surgery 
(RR 1.3; 95% CI: 0.9-2.1). However, we found strong evidence of surgery after 60 days in 
multimorbid CRC patients compared to patients with no comorbidity. Patients affected by 
multimorbidity had 2.4 times the risk of being offered late surgery compared to emergency 
surgery (0 days) (ARR: 2.4; 95% CI: 1.4-4.1) (Table 3).  
 
Table 3. Multimorbidity risk factors by patient, tumor and healthcare characteristics among all 
incident colorectal cancer patients in Granada and Girona, 2011, n = 1,061 
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Multimorbidity vs. Non-comorbidity 
Comorbidities distribution across levels of covariates 
 
n(%) CRR(95%CI) P-value  ARR(95%CI) 
Patient's factors  Total 
     Age in years 
   
<0.001
 
<55 130 11(8.5) (Reference) 
  
55 - 64 216 35(16.2) 2.5 (1.2, 5.2) 
  
65 - 74 269 93(34.6) 8.4 (4.2, 16.8) 
  
≥75 423 185(43.7) 14.7 (7.6, 28.8) 
  
Sex 
   
0.019 
 
Male 630 215(34.1) (Reference) 
  
Female 408 109(26.7) 0.6 (0.4, 0.9) 
  
Performance status Ecog score 
   
<0.001 
 
Normal (0)  257 40(15.6) (Reference) 
 
(Reference) 
Restricted but able to carry out light work (1) 422 154(36.5) 4.6 (3.0, 7.0) 
 
3.5 (2.2, 5.4) 
Restricted, unable to work but capable of selfcare (2) 82 36(43.9) 6.8 (3.6, 12.8) 
 
2.9 (1.4, 5.8) 
Restricted, capable of limited selfcare or disabled (3, 4) 40 25(62.5) 24.7 (8.1, 75.0) 
 
12.6 (3.9, 40.5) 
Smoking status 
   
0.006 
 
Current 130 40(30.8) (Reference) 
 
(Reference) 
Previous 297 113(38.1) 1.4 (0.8, 2.3) 
 
0.7 (0.4, 1.2) 
Never 503 137(27.2) 0.7 (0.5, 1.1) 
 
0.3 (0.2, 0.5) 
BMI in kg/m2 
      
<25 226 57(25.2) (Reference) 0.002 (Reference) 
25.0 - 29.9 326 89(27.3) 1.0 (0.7, 1.5) 
 
1.0 (0.6, 1.6) 
≥30 193 79(40.9) 2.2 (1.4, 3.4) 
 
2.4 (1.4, 4.0) 
Tumor factors 
   
 
   
   
0.414 
 
 
Right colon 
 
348 
 
 
118(33.9) (Reference) 
 
(Reference) 
Left colon 335 104(31.0) 0.8 (0.6, 1.2) 
 
0.9 (0.6, 1.2) 
Colon Unspecified 7 3(42.9) 0.7 (0.5, 1.1) 
 
0.8 (0.6, 1.2) 
Rectal 348 99(28.5) 0.8 (0.2, 3.7) 
 
1.0 (0.2, 5.8) 
    
0.821 
 
I 158 44(27.8) (Reference) 
 
(Reference) 
II 592 189(31.9) 1.2 (0.8, 1.9) 
 
1.0 (0.6, 1.5) 
III-IV 96 27(28.1) 1.0 (0.5, 1.8) 
 
0.7 (0.4, 1.4) 
    
0.163 
 
I 167 47(28.1) (Reference) 
 
(Reference) 
II 276 99(35.9) 1.7 (1.0, 2.6) 
 
1.2 (0.7, 1.9) 
III 279 89(31.9) 1.2 (0.8, 1.9) 
 
1.1 (0.7, 1.8) 
IV 265 72(27.2) 1.0 (0.6, 1.7) 
 
0.9 (0.5, 1.4) 
Healthcare factors 
      Type hospital admission 
   
0.175 
 
Emergency 179 42(23.5) 0.7 (0.5, 1.1) 
 
0.6 (0.4, 1.0) 
Planned  682 206(30.2) (Reference) 
 
(Reference) 
Surgery  
 
  
<0.001 
 Done 864 249(28.8) (Reference) 
 
(Reference) 
Not done 171 73(42.7) 1.4 (0.9 2.2) 
 
1.3 (0.9, 2.1) 
Type of Surgery  
 
  
0.623 
 Major 801 235(29.3) 1.3 (0.6, 2,9) 
 
1.0 (0.5, 2,4) 
Minor 43 11(25.6) (Reference) 
 
(Reference) 
Time to surgery in months  
 
  
0.017 
 Emergency 0 days 168 33(19.6) (Reference) 
 
(Reference) 
1 to <14 days 111 26(23.4) 1.2 (0.6, 2.3) 
 
1.2 (0.6, 2.4) 
14 to 30 days 118 32(27.1) 1.4 (0.8, 2.5) 
 
1.3 (0.7, 2.5) 
31 to 59 days 188 60(31.9) 2.0 (1.2, 3.5) 
 
2.1 (1.2, 3.7) 
 60 and more days 278   98(32.2) 2.0 (1.2, 3.3)     2.4 (1.4, 4.1) 
CRR: Crude Risk Ratio; ARR: Adjusted Risk Ratio 
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Furthermore, the complete visualization of CoMCoR study results is provided at the 
following link http://watzilei.com/shiny/CoMCoR/.  
 
Discussion 
Overall, comorbidity is commonly recognized as being associated with cancer outcomes 
and survival [21]. However, there is an international sparsity of population-based 
epidemiological studies describing the prevalence of comorbidities and associated risk factors 
among cancer patients [22]. CoMCoR study fills this gap, providing translational evidence 
regarding the pattern of the prevalence of comorbidities, multimorbidity, and associated risk 
factors among CRC patients in Spain. The pattern is mainly characterized by a higher prevalence 
of diabetes, advanced cancer stage, and late surgery or no surgical treatment in older patients 
with dementia. 
 
To the best of our knowledge, the CoMCoR study presented here is the first to identify 
the most prevalent comorbidities and associated risk factors among CRC patients in Spain, and 
characterize a particular pattern in the distribution and frequency of comorbidities and 
multimorbidity. While clinical studies are representative of only a selected part of the population, 
CoMCoR is a high-resolution population-based observational study using cancer registration and 
hospital medical records that translates its results into clinical practice based on real-world data.  
 
Regarding the prevalence of comorbidities, we found that diabetes is the most prevalent 
comorbidity among CRC patients (24%). Among non-cancer populations, the prevalence of any 
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type of diabetes in adults in Spain has been reported to range between 6 and 11% [23]. However, 
there is a scarcity of literature reporting the prevalence of diabetes among CRC patients [22]. 
Our findings were similar to those previously reported in a Taiwanese cohort of 1,197 CRC 
patients where 24% had either a reported history of diabetes or were currently taking one or more 
diabetes-controlling medications [24]. Some evidence shows that diabetes is associated with 
higher incidence of CRC and shorter CRC survival [25]. Thus, we argue that public health 
programs targeting cancer prevention strategies among diabetic patients might have a positive 
impact on CRC outcomes in Spain. 
 
Furthermore, we found a high prevalence of advanced stage cancer diagnosis (stage 
III/IV) among all CRC patients, which was even higher in older CRC patients affected by 
dementia. We argue that this may be due to low utilization of CRC screening in Spain. In 2011, 
CRC screening programs were implemented in only nine Spanish regions, with just partial 
coverage [26]. While all populations would benefit from the systematic use of screening, 
socioeconomically disadvantaged groups, such as patients with dementia, may also benefit from 
a targeted CRC screening [27].  
 
Comorbid medical diseases are highly prevalent among elderly. Overall, over 60% of all 
cases of cancer are diagnosed after age 65 years, with 67% of cancer deaths occurring in this age 
group [28]. We found a high prevalence of older patients not being offered surgical treatment, 
but it was even higher for older patients with stage III/IV CRC and dementia. There are many 
reasons why cancer occurs more frequently in older persons. The elderly have less resistance and 
longer exposure to carcinogens, a decline in immune system functioning, an alteration in anti-
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tumor defenses, decreased DNA repair, defects in tumor-suppressor genes, and differences in 
biological behavior, including angiogenesis. These factors contribute to the elderly population 
often being affected by comorbidities which affect cancer diagnosis, treatment, and survival [29]. 
The high prevalence we found of older CRC patients not being offered surgical treatment in 
stages III and IV partially it might reflect the low uptake and partial coverage of CRC screening 
and preventive strategies in Spain.  
 
Regarding multimorbidity, we found that it is associated with late surgery (≥60 days after 
cancer diagnosis) and emergency surgery offered the same day of an emergency hospital 
admission. Recently published evidence has shown that CRC diagnosed after a hospital 
emergency room admission were more likely associated with older and more socioeconomically 
deprived individuals [30]. Although disease stage at the time of diagnosis of CRC is a crucial 
determinant of patient outcome, comorbidity increases the complexity of cancer management 
and affects survival duration. Cancer control and treatment research questions should address 
multimorbidity, particularly in the elderly [31]. Regarding the evidence examining time from 
cancer diagnosis to surgical treatment there is no conclusive evidence supporting an optimal 
window of time. However, a study from the American College of Surgeons has found that 
patients who had a cancer operation at precisely eight weeks (56 days) after the end of combined 
chemoradiotherapy had the best overall survival and successful removal of their residual tumors 
[32]. Other study found that CRC patients waiting longer than 12 weeks (84 days) to receive 
surgery had increased all-cause mortality compared with patients receiving surgery within four 
weeks (28 days) [33]. In a study of patients receiving elective surgery for colonic resection 
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following diagnosis with CRC in Ontario, it was found that factors influencing receipt of 
treatment after 42 days from diagnosis included older age and comorbidity [34].  
 
Emergency surgery was defined as surgery offered the same day of an emergency 
hospital admission. Thus, we were assuming implicitly that CRC was diagnosed as a 
consequence of an emergency surgical intervention. However, we do not have empirical data to 
support our assumption. On the other hand, 30% of emergency surgery was performed among 
older advanced-stage CRC patients with dementia. It has been shown that CRC diagnosed after a 
hospital emergency admission is more likely associated with older and more deprived individuals 
[35, 36]. Recently, a study showed that 18% of CRC cases that were diagnosed as emergency 
cases had “red flag” symptoms, indicating the disease could have been identified earlier [30]. 
The promotion of CRC symptom awareness among the elderly might help them to early identify 
these symptoms and visit their general practitioner, who must refer them through the normal 
pathways to specialist evaluation [30]. 
 
There have been attempts to reanalyze the different comorbidity scores and their 
weighting algorithms, which show that some diseases should have a higher weight (including 
dementia), and others a lower weight (including peptic ulcers). Different approaches to 
measuring comorbidity specifically in cancer patients include focusing on single comorbid 
conditions in isolation, or weighted indices such as the Charlson comorbidity index [37], the 
Adult Comorbidity Evaluation – 27 index (ACE-27) [38], or the Elixhauser index [39]. However, 
to date, there is no agreed gold standard method upon which to measure comorbidity in the 
cancer patient population [40]. We used the Royal College of Surgeons system, which is a 
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clinical score used to evaluate the risk of death during surgery. The score applies an equal weight 
system to 12 different comorbidities categorized into 0, 1, 2 or more comorbidities, making it 
easy-to-use, since all comorbidities are considered equally important [18].  
 
We assumed that missing data were completely at random and performed a complete case 
analysis, which might introduce bias if the data were actually missing at random. However, our 
CoMCoR study was merely descriptive, and the percentage of missing data for the main outcome 
(comorbidities) was only 2%. Also, we would like to acknowledge the limited scope of the 
analysis in terms of time and space, with only one calendar year of CRC incident cases and two 
population-based cancer registries, thus limiting the external validity of our findings and 
supporting the need of more studies. 
 
In summary, the CoMCoR study has identified a consistent pattern in the distribution and 
frequency of comorbidities and multimorbidity for CRC patients in Spain, mostly associated 
with diabetes, dementia, advanced cancer diagnosis, older age, and surgical treatment. The high 
prevalence of CRC diagnosed at stage III/IV among elderly patients and patients with dementia 
and the high prevalence of older patients not being offered surgical treatment are significant 
findings that require immediate policy actions. Results from the CoMCoR study may help to 
foster CRC screening and preventive strategy policies in Spain and other countries. 
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